Last 12 months
Inside the activity.
0 purchase rows · 64 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 34 |
| Jan 2026 | 0 | 21 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2018 Filed Dec 28, 2018 22:20 UTC |
GIVEN DOUGLAS BDirector
|
SaleCommon Stock | 3,000 | $12.00 | $36,000.00 |
DisclosureSEC source: 0001209191-18-064340 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,130 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 22:15 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 90,000 | $13.92 | $1,252,800.00 |
DisclosureSEC source: 0001209191-18-063963 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,542,455 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.92 to $13.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 333,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 00:40 UTC |
Ferrari MauroDirector
|
GrantCommon Stock | 3,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063581 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,227 F1 · balance_after: This balance reflects the cancellation of 50,000 restricted stock units that were previously granted and reported on January 1, 2017. Dr. Ferrari's employer limits the amount of compensation he can take, and as such, these restricted stock units were subsequently cancelled. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 22:18 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon STock | 90,000 | $14.07 | $1,266,300.00 |
DisclosureSEC source: 0001209191-18-062779 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,632,455 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.58 to $14.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 513,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 02:09 UTC |
GIVEN DOUGLAS BDirector
|
SaleCommon Stock | 3,000 | $12.74 | $38,220.00 |
DisclosureSEC source: 0001209191-18-059974 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,130 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.58 to $12.76, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| November 09, 2018 Filed Nov 10, 2018 00:01 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 5,300 | $14.95 | $79,235.00 |
DisclosureSEC source: 0001209191-18-058026 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,722,455 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.92 to $15.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes a total of 693,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| November 09, 2018 Filed Nov 10, 2018 00:01 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 76,200 | $14.35 | $1,093,470.00 |
DisclosureSEC source: 0001209191-18-058026 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,727,755 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.87 to $14.85, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 00:06 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 3,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056001 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,130 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC |
Leone Peter BrianVP, Strategic Bus. Initiatives
|
Exercise / conversionStock Options · Derivative | 66,762 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · derivative · entry 7 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,863 Underlying: Common Stock · 66,762 shares Expires 2025-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC |
Leone Peter BrianVP, Strategic Bus. Initiatives
|
Exercise / conversionStock Options · Derivative | 34,375 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · derivative · entry 6 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,625 Underlying: Common Stock · 34,375 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC |
Leone Peter BrianVP, Strategic Bus. Initiatives
|
Exercise / conversionStock Options · Derivative | 30,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · derivative · entry 5 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 30,000 shares Expires 2023-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC |
Leone Peter BrianVP, Strategic Bus. Initiatives
|
SaleCommon Stock | 131,137 | $13.49 | $1,769,038.13 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · nonDerivative · entry 4 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 F1 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.10 to $13.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC |
Leone Peter BrianVP, Strategic Bus. Initiatives
|
Exercise / conversionCommon Stock | 66,762 | $7.75 | $517,405.50 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · nonDerivative · entry 3 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC |
Leone Peter BrianVP, Strategic Bus. Initiatives
|
Exercise / conversionCommon Stock | 34,375 | $6.15 | $211,406.25 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · nonDerivative · entry 2 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC |
Leone Peter BrianVP, Strategic Bus. Initiatives
|
Exercise / conversionCommon Stock | 30,000 | $2.79 | $83,700.00 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · nonDerivative · entry 1 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · derivative · entry 6 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 20,000 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · derivative · entry 5 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,000 Underlying: Common Stock · 25,000 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 20,000 | $21.01 | $420,200.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 25,000 | $18.00 | $450,000.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 20,000 | $4.75 | $95,000.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 25,000 | $2.62 | $65,500.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:23 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 64,834 | $14.45 | $936,851.30 |
DisclosureSEC source: 0001209191-18-049552 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,803,955 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $14.65, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes a total of 856,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 20:23 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 100,000 | $14.45 | $1,445,000.00 |
DisclosureSEC source: 0001209191-18-049552 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,868,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.40 to $14.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 01:18 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-18-038884 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 01:18 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 20,000 | $14.01 | $280,200.00 |
DisclosureSEC source: 0001209191-18-038884 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 01:18 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 20,000 | $2.01 | $40,200.00 |
DisclosureSEC source: 0001209191-18-038884 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 21:34 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,600 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · derivative · entry 6 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,000 Underlying: Common Stock · 12,600 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 21:34 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 12,600 | $11.00 | $138,600.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 21:34 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 12,600 | $2.01 | $25,326.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:34 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · derivative · entry 5 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,600 Underlying: Common Stock · 1,400 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:34 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 1,400 | $11.00 | $15,400.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:34 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 1,400 | $2.01 | $2,814.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2018 Filed Apr 25, 2018 23:40 UTC |
GIVEN DOUGLAS BDirector
|
SaleCommon Stock | 25,000 | $6.63 | $165,750.00 |
DisclosureSEC source: 0001209191-18-026146 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.48 to $6.89, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 23:46 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-18-021843 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 23:46 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 20,000 | $8.00 | $160,000.00 |
DisclosureSEC source: 0001209191-18-021843 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 23:46 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 20,000 | $2.01 | $40,200.00 |
DisclosureSEC source: 0001209191-18-021843 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2018 Filed Mar 16, 2018 22:09 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 26,000 | $7.40 | $192,400.00 |
DisclosureSEC source: 0001209191-18-020349 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,968,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.40 to $7.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 1,186,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| March 15, 2018 Filed Mar 15, 2018 22:58 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 100,000 | $7.41 | $741,000.00 |
DisclosureSEC source: 0001209191-18-019971 · doc4.xml · nonDerivative · entry 3 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,994,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The prices reported on Column 4 are a weighted average prices. The shares sold on 3/13/18 were sold in multiple transactions at prices ranging from $7.29 to $7.56, inclusive. The shares sold on 3/14/18 were sold in multiple transactions at prices ranging from $7.26 to $7.69, inclusive. The shares sold on 3/15/18 were sold in multiple transactions at prices ranging from $7.40 to $7.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 1,186,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 22:58 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 100,000 | $7.44 | $744,000.00 |
DisclosureSEC source: 0001209191-18-019971 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The prices reported on Column 4 are a weighted average prices. The shares sold on 3/13/18 were sold in multiple transactions at prices ranging from $7.29 to $7.56, inclusive. The shares sold on 3/14/18 were sold in multiple transactions at prices ranging from $7.26 to $7.69, inclusive. The shares sold on 3/15/18 were sold in multiple transactions at prices ranging from $7.40 to $7.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:58 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 100,000 | $7.43 | $743,000.00 |
DisclosureSEC source: 0001209191-18-019971 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,194,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The prices reported on Column 4 are a weighted average prices. The shares sold on 3/13/18 were sold in multiple transactions at prices ranging from $7.29 to $7.56, inclusive. The shares sold on 3/14/18 were sold in multiple transactions at prices ranging from $7.26 to $7.69, inclusive. The shares sold on 3/15/18 were sold in multiple transactions at prices ranging from $7.40 to $7.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 01:48 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 20,000 | $6.73 | $134,600.00 |
DisclosureSEC source: 0001209191-18-016994 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,356 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units on 03/05/2018. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.77, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 01:46 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Tax withholdingCommon Stock | 8,208 | $6.66 | $54,665.28 |
DisclosureSEC source: 0001209191-18-016992 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: This transaction reflects the payment of the tax liability by withholding securities incident to the vesting of restricted stock units on 03/05/2018. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:46 UTC |
Waddill William D.Director
|
GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001549 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 01:06 UTC |
FRYKMAN EDWARD WDirector
|
GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001573 · doc4.xml · nonDerivative · entry 1 FRYKMAN EDWARD W · CIK 0001078202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,852 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:42 UTC |
PERRY MICHAEL SDirector
|
GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001536 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:39 UTC |
GIVEN DOUGLAS BDirector
|
GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001530 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:36 UTC |
Leone Peter BrianVP, Strategic Bus. Initiatives
|
GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001523 · doc4.xml · nonDerivative · entry 1 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:31 UTC |
O'Brien PatrickGeneral Counsel
|
GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001499 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:28 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001480 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,023 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:25 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 20,000 | $3.69 | $73,800.00 |
DisclosureSEC source: 0001209191-18-001466 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,356 F2 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units on 01/01/2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.